Half of providers tie diabetes treatment success to managing patient’s emotions
PRINCETON, N.J. — Major portions of the American population with diabetes believe that their care requires much more than medicine, including emotional support and lifestyle management, and that diabetes care reimbursement needs to be broadened, according to a Novo Nordisk survey published Wednesday.
The survey, called Diabetes 360, found that nearly half (45%) of healthcare practitioners surveyed tied their success in caring for people with diabetes to their ability to understand and manage the emotional issues their patients face. As many as 42% of diabetes patients surveyed reported they feel guilty or anxious when they get off track with their diabetes management, and almost one-third of diabetes patients feel overwhelmed by their disease state. As many as 30% of patients surveyed believe that diabetes takes up too much of their mental and physical energy every day.
"In my years as both a patient and physician, I've been on all sides of the exam table. While medication is an obvious component of managing diabetes, it's only a fraction of the whole picture," stated Todd Hobbs, chief medical officer at Novo Nordisk. "It is critical to holistically understand patient needs and potential burdens, beyond just those related to their medication. And this is exactly what Novo Nordisk set out to do through the Diabetes 360 Survey. We're taking a full 360 view of patient care so we can serve their needs even better."
Not unexpected were findings on affordability, with two-thirds of HCPs believing access to new medicines should be improved. Approximately half (51%) of patients wanted medications to be more affordable. In addition, 22% reported difficulty in paying for their diabetes medications, and 8% of patients reported not filling their medication prescription due to cost.
The survey, conducted by Research Partnership, an independent healthcare market research and consulting agency, builds on Novo Nordisk's focus on addressing patient hurdles in the constantly evolving healthcare landscape, including creating new affordability options to lower out-of-pocket medicine costs. In 2001, Novo Nordisk launched Diabetes Attitudes, Wishes and Needs – a global partnership initiative for the advancement of patient-centered diabetes care.
The goal of Diabetes 360 is to strengthen collaboration across the diabetes community to make a meaningful difference in patients' lives.
Mayne Pharma launches generic Clozaril
GREENVILLE, N.C. — Mayne Pharma’s newest portfolio addition is its generic of Clorazil (clozapine) tablets. The antipsychotic is indicated to treat severely ill patients with schizophrenia and to reduce the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder.
“The launch of the full range of Clozapine tablets is our sixth product launch in 2017 and will further diversify our product offering,” Mayne Pharma CEO Scott Richards said.
Richards noted that the Clozaril generic — currently supplied by Teva — would ultimately be manufactured at Mayne Pharma’s Greenville, N.C. facility that is set to open in early 2018. The solid oral dose facility is set to quadruple the company’s U.S. manufacturing capacity, Richards said.
The company’s Clozaril generic will be available in 25-, 50-, 100- and 200-mg dosage strengths. The treatment had U.S. sales of roughly $130 million for the 12 months ended July 31, according to QuintilesIMS data. The drug was approved under a Risk Evaluation and Management Strategy called the Clozapine REMS Program.
Diplomat accompanies solid Q3 results with another acquisition
FLINT, Mich. — Diplomat Pharmacy this week is demonstrating how it is continuing its growth — both organically and through acquisitions. Alongside its solid third-quarter results, the company announced its acquisition of Pharmaceutical Technologies, which does business as National Pharmaceutical Services.
The Omaha-based pharmacy benefits manager has a proprietary claims-processing system and offers mail-order services through its Integrated HMO Pharmacy. According to its current CEO Shellie Schoenig, the company was founded by pharmacists to address such issues as inefficiency and high costs as a way to differentiate itself.
Diplomat’s CEO and chairman, Phil Hagerman, said the acquisition — which will see Diplomat paying $31 million in cash and $16 million in stock — is a way of responding to patient and employer demands for flexible methods aimed at improving outcomes and reduced costs.
“Enhancing our managed markets strategy with PBM services expands Diplomat’s service offerings from a specialty pharmacy provider to a broader health care company,” Hagerman said. “This further positions us to offer necessary services to our partners throughout the industry. hese services impact outcomes and cost as the industry pushes toward value-based care.”
Diplomat’s move toward an expanded scope as a company comes as it posted increased gross margin, even as it saw a slight dip in sales and prescriptions. For the quarter ended Sept. 30, Diplomat dispensed 222,000 prescriptions — down from the prior-year period, which saw 266,000 prescriptions dispensed. However, the company’s gross margin increased to 7.6%, compared with 6.6% a year ago, with gross profit per prescription hitting $360, compared with $289. Total revenue was $1.13 billion, compared with 1.18 billion a year ago.
“Diplomat’s third quarter results were solid as we achieved financial results in-line with our expectations, experienced continued growth in our oncology and infusion businesses and expansion in our access to limited distribution drugs, as well as encouraging trends within the specialty pharmacy industry,” Hagerman said.
The company also settled arbitration with CVS Health, moving to a direct contract with the healthcare company. Besides the NPS acquisition, Diplomat acquired 8th Software, which Hagerman said also broadened the company’s service offerings, and helped build out an executive team to implement the company’s growth strategy (Diplomat named 8th Day Software founder Dave Loschinskey its chief information officer as part of the acquisition).